Verrica Pharmaceuticals Inc (VRCA)
Verrica Pharmaceuticals Inc. is a healthcare company focused on dermatology therapeutics in the United States. The company develops and commercializes treatments for skin-related diseases, including YCANTH (VP-102), a drug-device combination based on a controlled formulation of cantharidin for molluscum in adults and children, as well as common warts. Verrica is also advancing VP-315, an injectable oncolytic peptide-based therapy that is in phase II testing for dermatology oncology uses such as basal cell carcinoma and other related indications. The company has collaboration and license agreements with Torii Pharmaceutical Co., Ltd. for molluscum and common wart products in Japan, and with Lytix Biopharma AS for VP-315 in malignant and pre-malignant dermatological indications. Incorporated in 2013, Verrica Pharmaceuticals is headquartered in West Chester, Pennsylvania, and its common stock is listed on NASDAQ under the symbol VRCA.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VRCA
|
$7.52
|
36.0% Upside
|
Undervalued
|
$15.54
|
181.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-5.3x
|
5.9x
|
2.6x
|
94.312 M
|
75.841 M
|
1.5%
|
46.0%
|
-9.2
|
—
|
79.2%
|
